Business Description
XORTX Therapeutics Inc
NAICS : 325410
SIC : 3741
ISIN : CA98420Q1081
Total Employee Number:
3Description
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 16.33 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 54 | |||||
3-Year EPS without NRI Growth Rate | 53.6 | |||||
3-Year FCF Growth Rate | 52.2 | |||||
3-Year Book Growth Rate | -58.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.18 | |||||
9-Day RSI | 43.34 | |||||
14-Day RSI | 43.41 | |||||
3-1 Month Momentum % | -30.36 | |||||
6-1 Month Momentum % | -25.95 | |||||
12-1 Month Momentum % | -50.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.86 | |||||
Quick Ratio | 0.86 | |||||
Cash Ratio | 0.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -60.9 | |||||
Shareholder Yield % | -57.89 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -135.02 | |||||
ROA % | -98.47 | |||||
ROIC % | -193.48 | |||||
3-Year ROIIC % | -12997.26 | |||||
ROC (Joel Greenblatt) % | -7408.3 | |||||
ROCE % | -152.04 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.33 | |||||
Price-to-Tangible-Book | 2.74 | |||||
EV-to-EBIT | -1.09 | |||||
EV-to-EBITDA | -1.13 | |||||
EV-to-Forward-Revenue | 1.25 | |||||
EV-to-FCF | -1.27 | |||||
Earnings Yield (Greenblatt) % | -91.74 | |||||
FCF Yield % | -73.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XRTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
XORTX Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.48 | ||
| Beta | 1.2235 | ||
| 3-Year Sharpe Ratio | -1.19 | ||
| 3-Year Sortino Ratio | -1.35 | ||
| Volatility % | 62.92 | ||
| 14-Day RSI | 43.41 | ||
| 14-Day ATR ($) | 0.129958 | ||
| 20-Day SMA ($) | 2.080205 | ||
| 12-1 Month Momentum % | -50.93 | ||
| 52-Week Range ($) | 1.725 - 7.05 | ||
| Shares Outstanding (Mil) | 1.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
XORTX Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
XORTX Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 111 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 20 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 2.01 (-1.95%) | ||
| 0.2:1 Stock Split | 2026-04-06 | 2.15 (+10.41%) | ||
| General meeting for 2026 | 2026-03-24 10:00 | 2.03 (-1.70%) | ||
| Annual report for 2025 | 2026-02-26 | 2.00 (-2.20%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 2.80 (-2.77%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 4.40 (-3.30%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 4.94 (-0.11%) | ||
| Annual report for 2024 | 2025-03-25 | 4.95 (-3.88%) |
Show
Entries
XORTX Therapeutics Inc Frequently Asked Questions
What is XORTX Therapeutics Inc(XRTX)'s stock price today?
The current price of XRTX is $2.03. The 52 week high of XRTX is $7.05 and 52 week low is $1.73.
When is next earnings date of XORTX Therapeutics Inc(XRTX)?
The next earnings date of XORTX Therapeutics Inc(XRTX) is 2026-08-14 Est..
Does XORTX Therapeutics Inc(XRTX) pay dividends? If so, how much?
XORTX Therapeutics Inc(XRTX) does not pay dividend.
Guru Commentaries on NAS:XRTX
No articles.
Press Release
Articles on XORTX Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers